Clinical characteristics and prognostic factors of 41 patients with mantle cell lymphoma
10.7644/j.issn.1674-9960.2023.12.010
- VernacularTitle:41例套细胞淋巴瘤患者临床特点及预后因素分析
- Author:
Shihua ZHAO
1
;
Qiushi YANG
;
Xilin CHEN
;
Xiubin XIAO
Author Information
1. 解放军总医院第五医学中心血液病医学部淋巴瘤浆细胞疾病科,北京 100071
- Keywords:
mantle-cell lymphoma;
rituximab;
clinical study;
prognosis
- From:
Military Medical Sciences
2023;47(12):942-946
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinical characteristics,treatment regimens and influencing factors of prognosis of patients with mantle cell lymphoma(MCL).Methods The clinical data of 41 patients with MCL was collected.These patients were initially diagnosed and treated in the Fifth Medical Center of Chinese PLA General Hospital between August 2004 and December 2019.The clinical features,therapeutic efficacy and prognosis-related factors were clarified.Results The median duration of follow-up was 68(1-165)months.The 3-year progression free survival(PFS)and overall survival(OS)were 37.29%and 62.75%respectively.Based on univariate analysis,B symptoms,Eastern Cooperative Oncology Group(ECOG)scores,the mantle cell lymphoma international prognostic index(MIPI),relapse and refractory state and the therapeutic effect were statistically significant for progression free survival.B symptoms,R-chemotherapy and therapeutic effect were statistically significant for overall survival.In multivariate analysis,B symptoms and the MIPI were statistically significant for progression free survival.B symptoms,R-chemotherapy and therapeutic effect were statistically significant for overall survival.There were statistically significant differences in 3-year OS between patients with different MIPI and MIPI-C scores.Conclusion Mantle cell lymphoma mostly occurs in elder males,and is more likely to be detected in late the stage.B symptoms,R-chemotherapy and therapeutic effect are independent prognostic factors for patients with MCL.The MIPI and MIPI-C scores have clinical guidance significance for patient survival.
